Compare Beyond Meat Inc (BYND) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Cassava Sciences Inc — how do they compare? Beyond Meat Inc trades at $0.4 (market cap $215.41M), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Beyond Meat Inc is far larger — about 4.5× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| BYND | FLNA | |
|---|---|---|
Market Cap | $215.41M | $47.75M |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $4.64 |
52-Week Low | $0.42 | $0.87 |
Enterprise Value | $455.69M | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.40, down 22.6% amid a 30:1 reverse stock split announced August 14, 2026. Despite beating Q2 2026 EPS estimates, revenue has declined from $419M in 2022 to $275M in 2025. The stock shows bearish technical signals with oversold RSI readings. Analyst consensus is heavily bearish with 57% sell ratings, reflecting concerns over cash burn and market positioning.
The outlook remains challenging with declining revenues and negative operating cash flow. Investment opportunity exists if turnaround efforts succeed in international markets, but risks include persistent cash burn, competitive pressures, and execution uncertainty. The reverse split addresses listing requirements but doesn't resolve fundamental business challenges.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
